Episode 60
Biotech Hangout
00:00
The Impact of the FTC Intervening in the AMGIN Acquisition of Horizon
The FTC sued to block the $27.8 million AMGIN acquisition of Horizon claiming that the deal would stifle competition for thyroid eye disease and chronic refractory gout treatments. The IPO class of the last five years of that is a new creation in April 2004, according to Othello. So I just think while it's not super strong Daphne, I would just say you know return to normalcy might be actually a positive thing.
Transcript
Play full episode
